Cargando…
The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
INTRODUCTION: The Orphan Drug Act encourages drug development for rare conditions. However, some orphan drugs become top sellers for unclear reasons. We sought to evaluate the extent and cost of approved and unapproved uses of orphan drugs with the highest unit sales. METHODS: We assessed prescripti...
Autores principales: | Kesselheim, Aaron S., Myers, Jessica A., Solomon, Daniel H., Winkelmayer, Wolfgang C., Levin, Raisa, Avorn, Jerry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283698/ https://www.ncbi.nlm.nih.gov/pubmed/22363762 http://dx.doi.org/10.1371/journal.pone.0031894 |
Ejemplares similares
-
The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs
por: Bendicksen, Liam, et al.
Publicado: (2022) -
Top Selling (2026) Small Molecule Orphan Drugs: A Journey into Their Chemistry
por: Benedetto Tiz, Davide, et al.
Publicado: (2023) -
Microbiological contamination in counterfeit and unapproved drugs
por: Pullirsch, Dieter, et al.
Publicado: (2014) -
Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022) -
Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019
por: Clemans-Cope, Lisa, et al.
Publicado: (2023)